Gain Therapeutics climbs as Parkinson's therapy shows positive results

Gain Therapeutics

06/02/2024 14:08

** Shares of Gain Therapeutics  GANX.O  rise ~5.2% to $4.62
premarket
    ** Co says its therapy GT-02287 for Parkinson's disease
provided neuroprotection and restored motor function in a
preclinical study testing it against mice
    ** Parkinson's disease is a brain disorder that causes
unintended or uncontrollable movements
    ** Says co is currently conducting an early-stage human
trial for the therapy
    ** Up to last close, stock up 11% in the last 12 months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))